Edition:
United Kingdom

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

2.96USD
4:11pm BST
Change (% chg)

$-0.03 (-1.00%)
Prev Close
$2.99
Open
$3.01
Day's High
$3.06
Day's Low
$2.95
Volume
49,037
Avg. Vol
411,946
52-wk High
$3.97
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Achillion Says Enrolled 23 Patients In Phase 2 Trials For C3 Glomerulopathy
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ENROLLMENT MILESTONE IN PHASE 2 TRIALS FOR C3 GLOMERULOPATHY.ACHILLION PHARMACEUTICALS INC - TARGETING END-OF-PHASE 2 MEETING WITH FDA IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC - ENROLLED 23 PATIENTS IN ACH-4471 PHASE 2 C3G SIX AND 12-MONTH CLINICAL TRIALS.ACHILLION PHARMACEUTICALS INC - REMAIN ON TRACK TO PRESENT DATA FROM TWO PHASE 2 TRIALS TO U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2019.  Full Article

Achillion Pharma Q4 Net Loss $16.6 Mln Vs Net Loss Of $23.2 Mln A Year Earlier
Thursday, 7 Mar 2019 

March 7 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC - WELL FUNDED WITH CASH AND SECURITIES OF $271 MILLION AT DECEMBER 31, 2018.ACHILLION PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION IN US FOR ACH-5228 IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC QTRLY REPORTED A NET LOSS OF $16.6 MILLION, COMPARED TO A NET LOSS OF $23.2 MILLION IN THREE MONTHS ENDED DEC 31, 2017.  Full Article

Achillion Announces First Dosing In Phase 1 Multiple Ascending Dose Study Of ACH-5228
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES FIRST DOSING IN PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF ACH-5228 NEXT-GENERATION ORAL FACTOR D INHIBITOR IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - ACHILLION PLANNING INVESTIGATIONAL NEW DRUG (IND) SUBMISSION IN Q4 OF 2019.ACHILLION PHARMACEUTICALS INC - PLANNING INVESTIGATIONAL NEW DRUG (IND) SUBMISSION IN Q4 OF 2019.  Full Article

Achillion Announces Nicole Vitullo Elected To Chair Board Of Directors
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES NICOLE VITULLO ELECTED TO CHAIR THE BOARD OF DIRECTORS.ACHILLION PHARMACEUTICALS INC - SCHEER WILL REMAIN ON BOARD OF DIRECTORS OF COMPANY.ACHILLION PHARMACEUTICALS INC - AS CHAIR, NICOLE VITULLO REPLACES DAVID SCHEER.  Full Article

Achillion Pharmaceuticals- Appointed Keri Lantz, on interim basis, to positions of principal financial officer, principal accounting officer
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION PHARMACEUTICALS-ON DEC 12, APPOINTED KERI LANTZ, ON INTERIM BASIS, TO POSITIONS OF PRINCIPAL FINANCIAL OFFICER, PRINCIPAL ACCOUNTING OFFICER.ACHILLION PHARMACEUTICALS-KERI LANTZ APPOINTMENT IS BEING MADE IN CONNECTION WITH DEPARTURE OF MARY KAY FENTON, COMPANY'S CURRENT CFO - SEC FILING.  Full Article

Achillion Reports Positive Interim Data For Ach-4471 Phase 2 Trials And Provides Clinical Development Strategy Update
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS POSITIVE INTERIM DATA FOR ACH-4471 PHASE 2 TRIALS AND PROVIDES CLINICAL DEVELOPMENT STRATEGY UPDATE.ACHILLION PHARMACEUTICALS INC - PROOF OF MECHANISM VALIDATED IN C3G, END OF PHASE 2 MEETING TARGETED FOR 4Q 2019.ACHILLION PHARMACEUTICALS INC - ACH-4471 PROOF OF CONCEPT VALIDATED IN BOTH PNH AS MONOTHERAPY AND IN COMBINATION W/C5 INHIBITOR.ACHILLION PHARMACEUTICALS INC - ACH-5228 PHASE 1MULTIPLE ASCENDING DOSE TRIAL TARGETED TO BEGIN JANUARY 2019.ACHILLION PHARMACEUTICALS - EXPECTED YE 2018 CASH,MARKETABLE SECURITIES BALANCE OF ABOUT $270 MILLION AND A PROJECTED 2019 CASH BURN OF $80-$85 MILLION.  Full Article

Achillion Pharmaceuticals Inc QTRLY Loss Per Share $0.12
Wednesday, 8 Aug 2018 

Achillion Pharmaceuticals Inc ::ACHILLION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC - JUNE 30, 2018 CASH POSITION $295.8 MILLION.ACHILLION PHARMACEUTICALS INC - COMPLETED DOSING PHASE 1 CLINICAL STUDY OF ACH-5228 AND INITIATED PHASE 1 STUDY OF ACH-5548.ACHILLION PHARMACEUTICALS INC - GLOBAL PHASE 2 CLINICAL PROGRAMS FOR ACH-4471 CONTINUE TO EXPAND IN PNH AND C3G.ACHILLION PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.12.  Full Article

Achillion Initiates Phase I First-In-Human Study Of ACH-5548
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN-HUMAN STUDY OF ACH-5548, A THIRD ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - CONTINUES TO ANTICIPATE PRESENTING RESULTS FROM A 14-DAY PHASE 2 CLINICAL TRIAL OF ACH-4471 IN C3G IN Q3 OF 2018.  Full Article

Achillion Initiates Phase I First-In Study Of ACH-5228
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018.  Full Article

Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY.ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.  Full Article